Anumana Introduced First-of-its-Kind Cardiac Amyloidosis Algorithm

Anumana has introduced the ECG-AI algorithm aimed for early identification of cardiac amyloidosis.

The ECG-AI algorithm is a medical technology that focuses on addressing the need for earlier identification of a specific underdiagnosed condition using electrocardiogram (ECG) data.

By leveraging the ECG-AI algorithm, medical practitioners can make timely decisions and provide necessary treatments, potentially saving lives and can potentially reach a broader population and contribute to the early identification of medical conditions that might otherwise go undiagnosed.

Cardiac amyloidosis is an underdiagnosed disease that often leads to heart failure. However, early diagnosis of this condition  can be difficult because  the disease is rare and often presents with nonspecific signs and symptoms. Although a standard ECG is obtained when evaluating these nonspecific symptoms,  subtle combinations of features that may indicate cardiac amyloidosis are often overlooked when interpreting a human ECG.

The FDA Breakthrough Device Designation granted to Cardiac Amyloidosis ECG-AI Algorithm is a testament to its remarkable potential in the early detection of this debilitating disease.